{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-22-000089","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.040137+00:00","generated_at":"2026-06-24T02:35:54.281842+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MacroGenics Q2 net loss $41.3M; cuts 15% workforce, extends cash runway to 2024","bullets":["Net loss $41.3M vs $39.9M YoY; cash $133.7M at June 30, plus $34.5M in July payments from partners.","Workforce reduction of ~15% and closure of Brisbane and Rockville sites to reduce costs.","Received $30M milestone from Incyte; $60M milestone due upon teplizumab approval (PDUFA Nov 17, 2022).","Plan to start MGC018 Phase 2/3 TAMARACK study in mCRPC by year-end; interim data from Phase 2 by end 2024.","Lorigerlimab Phase 1/2 enrollment complete; data update expected early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-22-000089","json":"https://secwatch.observer/filing/0001125345-22-000089.json","markdown":"https://secwatch.observer/filing/0001125345-22-000089.md","text":"https://secwatch.observer/filing/0001125345-22-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000089/0001125345-22-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000089/mgnx-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:35:54.281842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}